Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,018
  • Shares Outstanding, K 56,748
  • Annual Sales, $ 2,820 K
  • Annual Income, $ -127,500 K
  • EBIT $ -149 M
  • EBITDA $ -145 M
  • 60-Month Beta 1.03
  • Price/Sales 18.35
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.42
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +6.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8824 +18.99%
on 12/19/25
1.1900 -11.76%
on 11/28/25
-0.0600 (-5.41%)
since 11/26/25
3-Month
0.8824 +18.99%
on 12/19/25
2.5700 -59.14%
on 10/16/25
-0.8000 (-43.24%)
since 09/26/25
52-Week
0.8824 +18.99%
on 12/19/25
3.2100 -67.29%
on 01/03/25
-2.0600 (-66.24%)
since 12/26/24

Most Recent Stories

More News
TScan Therapeutics Announces Positive Updated Data from the ALLOHAâ„¢ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHAâ„¢ Phase 1 Trial and Future Market Opportunities

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA â„¢ Phase 1 heme trial to be presented at the 67 th American Society...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize...

TCRX : 1.0600 (+1.92%)
2 Overlooked Stocks to Snap Up in 2025

While much of Wall Street’s attention in 2025 centers around AI names, two under-the-radar companies are quietly getting stronger.

TCRX : 1.0600 (+1.92%)
ARDX : 5.76 (-3.84%)
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...

TCRX : 1.0600 (+1.92%)
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Two-year relapse data from ALLOHAâ„¢ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash...

TCRX : 1.0600 (+1.92%)
2 Small-Cap Stocks Under $10 to Buy With Big Potential

These high-risk, high-reward small-cap biotech stocks deserve a second look.

TCRX : 1.0600 (+1.92%)
JBIO : 16.52 (-0.06%)
AMGN : 331.57 (-0.72%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.1967
2nd Resistance Point 1.1333
1st Resistance Point 1.0867
Last Price 1.0600
1st Support Level 0.9767
2nd Support Level 0.9133
3rd Support Level 0.8667

See More

52-Week High 3.2100
Fibonacci 61.8% 2.3209
Fibonacci 50% 2.0462
Fibonacci 38.2% 1.7715
Last Price 1.0600
52-Week Low 0.8824

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar